002030.SZ
Daan Gene Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.39
−3.75%Aug 28, 2026, 11:16 UTC
Da An Gene announced its first-half 2026 results, reporting a net loss of 120 million yuan, an improvement from a loss of 182 million yuan in the same period of 2025.
Source:Aug 25, 2026, 01:01 UTC
Da An Gene and others jointly established Zhongda Synthetic Biotechnology (Guangzhou) Co., Ltd., a new company focused on synthetic biology research and development.
Source:Aug 18, 2026, 09:19 UTC
Da An Gene announced it obtained a medical device registration certificate from China's National Medical Products Administration for its human parainfluenza virus nucleic acid detection kit (fluorescent PCR method), valid until August 16, 2031.
Source:Aug 14, 2026, 11:24 UTC
Da An Gene's controlling shareholder Guangyong Technology completed industrial and commercial registration change on August 13, 2026, with its shareholder changed from Guangzhou Finance Holdings Group to Guangyao Capital, making Guangyao Capital the indirect controlling shareholder of Da An Gene with 16.63% equity.
Source:Aug 6, 2026, 09:20 UTC
Da'an Gene's wholly-owned subsidiary Guangzhou Databio Bioengineering Technology Co., Ltd. obtained a medical device registration certificate issued by the National Medical Products Administration for the alpha-fetoprotein assay kit (chemiluminescence method), valid until August 3, 2031.
Source:Jul 27, 2026, 01:51 UTC
Guangzhou Pharmaceutical Group acquired control of Daan Gene for about 2.418 billion yuan.
Source: